Show simple item record

dc.contributor.authorKierstead, Elexis C.en
dc.contributor.authorHarvey, Emilyen
dc.contributor.authorSanchez, Denisseen
dc.contributor.authorHorn, Kimberlyen
dc.contributor.authorAbroms, Lorien C.en
dc.contributor.authorSpielberg, Freyaen
dc.contributor.authorStanton, Cassandra A.en
dc.contributor.authorDebnam, Charlesen
dc.contributor.authorCohn, Amy M.en
dc.contributor.authorGray, Tiffanyen
dc.contributor.authorMagnus, Manyaen
dc.contributor.authorPatel, Minalen
dc.contributor.authorNiaura, Raymonden
dc.contributor.authorElf, Jessica L.en
dc.date.accessioned2021-01-11T12:40:55Zen
dc.date.available2021-01-11T12:40:55Zen
dc.date.issued2021-01-06en
dc.identifier.citationBMC Research Notes. 2021 Jan 06;14(1):2en
dc.identifier.urihttp://hdl.handle.net/10919/101824en
dc.description.abstractAbstract Objective Morbidity and mortality from smoking-related diseases among people living with HIV (PLWH) in the U.S. surpasses that due to HIV itself. Conventional smoking cessation treatments have not demonstrated strong efficacy among PLWH. We conducted a pilot randomized controlled trial (RCT) to evaluate a tailored smoking cessation intervention based on the minority stress model. We compared standard of care counseling (SOC) to a tailored intervention (TI) including one face-to-face counseling session incorporating cognitive behavioral therapy to build resilience, and 30 days of 2-way text messaging. Results The primary outcome was smoking cessation. Secondary outcomes included cigarettes per day (CPD), exhaled carbon monoxide (CO), and cessation self-efficacy. A total of 25 participants were enrolled (TI:11, SOC:14), and 2 were lost to follow-up. There were no significant differences in quit rates between study groups. However, there was a significantly greater decrease in CPD in the TI versus SOC (13.5 vs. 0.0, p-value:0.036). Additionally, self-efficacy increased in both groups (TI p-value:0.012, SOC p-value:0.049) and CO decreased in both groups (TI p-value: < 0.001, SOC p-value:0.049). This intervention shows promise to support smoking cessation among PLWH. A larger study is needed to fully evaluate the efficacy of this approach. Clinical trial: Trial Registration: Retrospectively registered (10/20/2020) NCT04594109.en
dc.format.mimetypeapplication/pdfen
dc.language.isoenen
dc.rightsCreative Commons Attribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.titleA pilot randomized controlled trial of a tailored smoking cessation program for people living with HIV in the Washington, D.C. metropolitan areaen
dc.typeArticle - Refereeden
dc.date.updated2021-01-10T04:14:06Zen
dc.rights.holderThe Author(s)en
dc.title.serialBMC Research Notesen
dc.identifier.doihttps://doi.org/10.1186/s13104-020-05417-3en
dc.type.dcmitypeTexten
dc.type.dcmitypeStillImageen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Creative Commons Attribution 4.0 International
License: Creative Commons Attribution 4.0 International